GILD Gilead Sciences Inc
XNAS
156.04
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
GILD
$156.04
—
Key stats
$156.04
- 52-Week Range
- $114.02 – $160.51
- YTD
- +28.32%
- IV Rank (30D)
- 81.76
- Straddle Price
- $12.55
- P/C Vol Ratio
- 0.62
- Market Cap
- $194.9B
- Open
- $156.47
- Day Range
- $155.76 – $157.65
- Volume
- 6,070,925
- Prev Close
- $157.19
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 0.62 |
| Cost of Equity (CAPM) | 8.22% (VRP-adj) |
| WACC | 7.93% |
| Volatility Risk Premium | +20.9pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +0.4% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.00 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $12.9B |
| Return on Equity (TTM) | -27.4% |
| Book / Price | 6.0% |
| Gross Margin (TTM) | 79.6% |
| FCF Margin (TTM) | 42.5% |
| Debt / Equity | 2.03 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +0.6% (reverse-DCF on current price) |
| SMA 50 | $148.48 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $150.77 |
| Bollinger Width / SMA20 | 7.2% (drives anchor stability) |
| Net Debt | $20.7B |
| Market Cap | $197B |
Peers used for multiples: ABBV, AMGN, JNJ, LLY, MRK, MRNA, REGN, VRTX
60-Day Conviction
6%
20-Day Fair Value
≈ by Nov 23, 2026
$158.02
α +1.3%
rank 8%
conviction
72%
40-Day Fair Value
≈ by Dec 22, 2026
$158.72
α +1.7%
rank 4%
conviction
55%
60-Day Fair Value
≈ by Jan 20, 2027
$156.26
α +0.1%
rank 5%
conviction
6%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $155.57 | 17% | |
| DDM (Gordon) | $41.95 | 14% | |
| Peer P/E | n/a | 0% | median 38.6× · 7 peers |
| Peer EV/EBITDA | $34.20 | 5% | median 19.6× · 7 peers |
| Peer P/B | $82.77 | 7% | median 8.8× · 7 peers |
| Peer P/S | $171.96 | 7% | median 7.0× · 8 peers |
| Market Anchor (SMA50) | $148.48 | 34% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $158.03 | 17% | 28 strikes · skew +0.12 |
As of 2026-10-23 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $194.9B
- Employees
- 17,000
- List Date
- 1992-01-22
- CIK
- 0000882095
- Next Earnings
- 2026-10-29 (After-Close)
- EPS Forecast
- $2.17 (6 est.)
- Headquarters
- Foster City, CA
- Homepage
- https://www.gilead.com
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 9.13% | -5.37% | -1.70% | -5.98% | 5.79% | 16.74% | 3.10% |
| Feb | -5.68% | -11.79% | -4.13% | -7.75% | 16.19% | 4.24% | -1.49% |
| Mar | 3.47% | -1.34% | 4.25% | 1.30% | -3.40% | -7.11% | -0.47% |
| Apr | -4.47% | -0.55% | -1.24% | -10.54% | -4.26% | -6.74% | -4.63% |
| May | 0.47% | 7.53% | -5.50% | -1.89% | 6.62% | 2.11% | 1.56% |
| Jun | 5.42% | -4.57% | 1.13% | 8.17% | 1.80% | -3.63% | 1.39% |
| Jul | -1.22% | -4.19% | -0.75% | 10.81% | 0.50% | 3.65% | 1.47% |
| Aug | 6.48% | 6.49% | 1.06% | 3.28% | -0.19% | 11.58% | 4.78% |
| Sep | -2.81% | -5.02% | -2.23% | 5.19% | -1.52% | -0.58% | -1.16% |
| Oct | -5.37% | 25.90% | 5.99% | 5.81% | 7.77% | 5.79%* | 7.65% |
| Nov | 5.01% | 10.70% | -4.48% | 3.43% | 3.11% | -- | 3.55% |
| Dec | 5.34% | -2.33% | 4.33% | -1.75% | -1.28% | -- | 0.86% |
| Total | 15.31% | 10.86% | -3.95% | 7.97% | 33.71% | 26.18% | 15.02% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $151.03
SMA 50: $148.84
SMA 200: $138.86
Current: $156.04
EMA 12: $153.66
EMA 26: $151.26
MACD: 2.4005 | Signal: 0.4814
BULLISH
ADX (14): 22.58
WEAK TREND
+DI: 27.84
−DI: 18.13
Momentum Oscillators
RSI (14): 58.43
NEUTRAL
Stoch %K: 72.59
Stoch %D: 70.62
Williams %R: -24.96
Volume & Volatility
BB Upper: $159.57
BB Lower: $142.49
NEUTRAL
OBV: 262,583,258
Vol SMA 20: 5,808,270
Vol ROC: 4.50%
ATR: $3.83
True Range: $1.89
HV 20: 28.3%
HV 30: 25.1%
HV 60: 25.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-25T00:00:00 – 2026-10-23T00:00:00
AI Analysis
Here is the stock analysis report for GILD:
Executive Summary
BULLISH (Confidence level: 7/10)
Key drivers:
- Strong technical momentum with MACD signal line crossover above 0 indicating bullish momentum.
- RSI neutral, indicating potential buy signal.
Primary risks:
- Volatility regime indicates low volatility, which may not be sustainable in the long term.
- Options market pricing a $8.98 move by expiration, indicating a significant price swing potential.
Investment thesis: GILD is poised for continued upside as it benefits from strong technical momentum and recent positive news headlines.
Recent news sentiment impact: The recent news headlines have been primarily neutral to positive, which has contributed to the stock's upward trend.
Technical Analysis
Trend Direction: Medium-term uptrend (1-3 months)
Support/Resistance Levels:
- SMA 20: $147.39 (strong support)
- SMA 50: $139.25 (medium-term resistance)
- Upper Bollinger Band: $151.94 (strong resistance)
Momentum Signals:
- MACD signal line crossover above 0 = bullish momentum.
- RSI neutral, indicating potential buy signal.
Volume Analysis:
- Volume rate of change: 39.91% (indicating increasing volume participation).
- On-Balance Volume (OBV): 371490005.70 (strong accumulation).
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been primarily focused on the biotech industry's growth potential and GILD's strong pipeline.
Sentiment Assessment: Aggregate sentiment is positive, with 4 out of 6 articles having a positive or neutral tone.
Catalyst Identification: Upcoming catalysts include continued innovation in CAR T-cell therapy and potential expansion into new therapeutic areas.
Market Narrative: The recent news headlines align with the technical signals, reinforcing the bullish momentum.
Risk & Volatility Assessment
Risk Assessment:
- Beta: 0.34 (low risk relative to market).
- Volatility regime: Low volatility.
- Options market signals: IV rank indicates medium volatility, and put/call ratios suggest a bullish sentiment.
Downside Protection: Support levels are provided by SMA 20 at $147.39 and the upper Bollinger Band at $151.94.
Market Context & Positioning
Sector Performance:
- Biotech sector has been performing strongly, with GILD benefiting from this trend.
Institutional Activity:
- Volume patterns suggest institutional interest, with increasing volume participation and strong accumulation on the OBV chart.
Correlation Analysis:
- Correlation coefficient: 0.16 (low correlation with the broader market).
Relative Valuation:
- Position within trading range: Bullish momentum has pushed GILD above its medium-term resistance at SMA 50.
Key Levels & Action Items
Critical Price Levels:
- SMA 20 at $147.39 (strong support).
- Upper Bollinger Band at $151.94 (strong resistance).
Breakout/Breakdown Levels:
- Breakout above SMA 50 at $139.25 could trigger significant upside.
- Breakdown below SMA 20 at $147.39 could lead to a correction.
Time-Sensitive Catalysts:
- Upcoming pipeline developments and potential expansion into new therapeutic areas.
Risk Management:
- Stop-loss levels: Set stop-loss orders around $145.00 to manage risk.
- Position sizing considerations: Consider scaling in positions as the stock approaches its medium-term resistance at SMA 50.
Please note that this analysis is based on the provided data, and actual market conditions may differ.
Generated
News
All GILD news →
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
The company's recent momentum continues unabated.
Shares of AbbVie, Eli Lilly and Gilead Sciences closed near record highs
Earnings History
14 of 23 under expected move
Avg Expected Move
4.40%
Avg Actual Move
3.87%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | After-Close | 2.82% | 0.69% | 0.24x | Within |
| 2021-04-29 | After-Close | 4.31% | 0.58% | 0.13x | Within |
| 2021-07-29 | After-Close | 2.78% | 2.21% | 0.79x | Within |
| 2021-10-28 | After-Close | 3.58% | 3.65% | 1.02x | Exceeded |
| 2022-02-01 | After-Close | 4.75% | 3.87% | 0.81x | Within |
| 2022-04-28 | After-Close | 3.75% | 3.61% | 0.96x | Within |
| 2022-08-02 | After-Close | 3.33% | 4.59% | 1.38x | Exceeded |
| 2022-10-27 | After-Close | 3.28% | 12.92% | 3.94x | Exceeded |
| 2023-02-02 | After-Close | 4.35% | 3.82% | 0.88x | Within |
| 2023-04-27 | After-Close | 3.75% | 1.60% | 0.43x | Within |
| 2023-08-03 | After-Close | 3.71% | 4.17% | 1.12x | Exceeded |
| 2023-11-07 | After-Close | 3.78% | 3.36% | 0.89x | Within |
| 2024-02-06 | After-Close | 3.94% | 4.25% | 1.08x | Exceeded |
| 2024-04-25 | After-Close | 3.80% | 0.23% | 0.06x | Within |
| 2024-08-08 | After-Close | 4.15% | 2.55% | 0.61x | Within |
| 2024-11-06 | After-Close | 4.42% | 6.77% | 1.53x | Exceeded |
| 2025-02-11 | After-Close | 6.10% | 7.46% | 1.22x | Exceeded |
| 2025-04-24 | After-Close | 4.89% | 2.81% | 0.57x | Within |
| 2025-08-07 | After-Close | 6.01% | 8.28% | 1.38x | Exceeded |
| 2025-10-30 | After-Close | 6.53% | 1.14% | 0.17x | Within |
| 2026-02-10 | After-Close | 5.50% | 5.82% | 1.06x | Exceeded |
| 2026-05-07 | After-Close | 5.81% | 2.04% | 0.35x | Within |
| 2026-08-04 | After-Close | 5.80% | 2.58% | 0.44x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
GILD Options Activity & IV Rank
GILD IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 36.1%
7-DTE IV: 49.6%
Expected Move: $12.55
7-DTE Move: $8.76
Days to Exp: 28 (2026-11-20)
Options Flow
Call Volume: 722
Put Volume: 449
P/C Volume: 0.622
BULLISH
Call OI: 25,658
Put OI: 19,870
P/C OI: 0.774
Total OI: 45,528
ATM Options Pricing
ATM Call: $6.95
ATM Put: $5.60
Call %: 4.5%
Put %: 3.6%
Chain Summary
Chain Volume: 12,968
Chain OI: 188,733
Last Updated: 10/23/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 63rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
63%
vs own history
GEX tilt
+0.46
OI-weighted, today
Vanna tilt
+0.56
δ-sensitivity to IV
Charm tilt
-0.68
δ-decay vs time
Vanna tilt +0.56: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.68: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 171 ATM contracts, 78k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
44%
+4.9
pts
EXTREME
as of Oct 23 · ATM 43.6% / Wing 48.5%
30 DTE / 10d
38%
+4.2
pts
EXTREME
as of Oct 23 · ATM 36.3% / Wing 40.5%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)74.9MediumOct 23
IV Rank (30 DTE)81.8HighOct 23
Straddle Price (30 DTE)$12.55Oct 23
Beta Analysis
Risk Metrics
Beta: 0.2872
Alpha: 25.55%
Correlation: 0.1362
R-Squared: 1.9%
Stock Volatility: 26.9%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own GILD
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $439.7M | #56 of 6285 | -12.6% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $280.1M | #35 of 3138 | +3.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $184.3M | #162 of 3716 | +23.6% | 13F | |
| Point72 Hedge fund Steve Cohen | $181.6M | #75 of 1945 | +16222.5% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $36.7M | #111 of 997 | +60.9% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $17.0M | #533 of 4729 | +29.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
GILD Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 1,251,500,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
52 filers$1.39B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $209.69M | 15.04% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $187.17M | 13.43% | 2026-06-30 |
| 3 | Caption Management, LLC | $170.26M | 12.21% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $136.33M | 9.78% | 2026-06-30 |
| 5 | Holocene Advisors, LP | $88.44M | 6.34% | 2026-06-30 |
| 6 | Millennium Management LLC Custodian | $54.59M | 3.92% | 2026-06-30 |
| 7 | Royal Bank of Canada Custodian | $40.86M | 2.93% | 2026-06-30 |
| 8 | JPMorgan Chase & Co Custodian | $40.59M | 2.91% | 2026-06-30 |
| 9 | Wolverine Trading, LLC Custodian | $38.27M | 2.75% | 2025-09-30 |
| 10 | IMC-Chicago, LLC Custodian | $33.72M | 2.42% | 2026-06-30 |
| 11 | Goldman Sachs Group Inc Custodian | $33.06M | 2.37% | 2026-06-30 |
| 12 | Walleye Trading LLC | $31.29M | 2.24% | 2026-06-30 |
| 13 | Simplex Trading, LLC Custodian | $28.74M | 2.06% | 2026-06-30 |
| 14 | TUDOR INVESTMENT CORP ET AL | $28.16M | 2.02% | 2026-06-30 |
| 15 | Walleye Capital LLC | $27.67M | 1.98% | 2026-06-30 |
| 16 | Barclays PLC Custodian | $25.27M | 1.81% | 2026-06-30 |
| 17 | ADAPT Investment Managers SA | $25.27M | 1.81% | 2026-06-30 |
| 18 | Alphadyne Asset Management LP | $23.36M | 1.68% | 2026-06-30 |
| 19 | Lombard Odier Asset Management (USA) Corp | $21.48M | 1.54% | 2026-06-30 |
| 20 | D. E. Shaw & Co., Inc. Custodian | $21.31M | 1.53% | 2026-06-30 |
| 21 | BNP Paribas Financial Markets Custodian | $19.92M | 1.43% | 2026-06-30 |
| 22 | UBS Group AG Custodian | $16.80M | 1.21% | 2026-06-30 |
| 23 | Citigroup Inc. Custodian | $11.12M | 0.80% | 2026-06-30 |
| 24 | GROUP ONE TRADING LLC Custodian | $10.40M | 0.75% | 2026-06-30 |
| 25 | PEAK6 LLC | $9.17M | 0.66% | 2026-06-30 |
44 filers$831.18M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $236.42M | 28.44% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $128.42M | 15.45% | 2026-06-30 |
| 3 | BNP Paribas Financial Markets Custodian | $82.77M | 9.96% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $45.55M | 5.48% | 2026-06-30 |
| 5 | Barclays PLC Custodian | $39.71M | 4.78% | 2026-06-30 |
| 6 | Millennium Management LLC Custodian | $36.49M | 4.39% | 2026-06-30 |
| 7 | JPMorgan Chase & Co Custodian | $26.68M | 3.21% | 2026-06-30 |
| 8 | ADAPT Investment Managers SA | $25.27M | 3.04% | 2026-06-30 |
| 9 | IMC-Chicago, LLC Custodian | $21.52M | 2.59% | 2026-06-30 |
| 10 | Goldman Sachs Group Inc Custodian | $20.21M | 2.43% | 2026-06-30 |
| 11 | Walleye Trading LLC | $18.00M | 2.17% | 2026-06-30 |
| 12 | Citigroup Inc. Custodian | $16.64M | 2.00% | 2026-06-30 |
| 13 | CAPSTONE INVESTMENT ADVISORS, LLC | $15.99M | 1.92% | 2026-06-30 |
| 14 | Wolverine Trading, LLC Custodian | $13.80M | 1.66% | 2025-09-30 |
| 15 | Alphadyne Asset Management LP | $11.96M | 1.44% | 2026-06-30 |
| 16 | Allianz Asset Management GmbH | $11.43M | 1.38% | 2026-06-30 |
| 17 | Simplex Trading, LLC Custodian | $10.99M | 1.32% | 2026-06-30 |
| 18 | Qube Research & Technologies Ltd | $7.95M | 0.96% | 2026-06-30 |
| 19 | Lombard Odier Asset Management (USA) Corp | $7.58M | 0.91% | 2026-06-30 |
| 20 | GROUP ONE TRADING LLC Custodian | $7.30M | 0.88% | 2026-06-30 |
| 21 | Eisler Capital Management Ltd. | $5.78M | 0.70% | 2025-09-30 |
| 22 | UBS Group AG Custodian | $4.84M | 0.58% | 2026-06-30 |
| 23 | Walleye Capital LLC | $4.26M | 0.51% | 2026-06-30 |
| 24 | Squarepoint Ops LLC | $3.83M | 0.46% | 2026-06-30 |
| 25 | CAPITAL FUND MANAGEMENT S.A. | $3.17M | 0.38% | 2026-06-30 |
GILD Insider Trading (Form 4)
Latest: 2026-10-16Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell (S) | −3,000 | $156.22 | -$468.7K | EDGAR |
| 2026-10-16 | Andrew D Dickinson | Chief Financial Officer | Sell (S) | −3,000 | $156.22 | -$468.7K | EDGAR |
| 2026-10-02 | Daniel Patrick O'Day | Chairman & CEO | Sell (S) | −15,000 | $147.90 | -$2.22M | EDGAR |
| 2026-09-23 | Erin Burkhart | SVP, Controllership | Mixed | +1,455 | $152.67 | -$117.3K | EDGAR |
| 2026-09-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell (S) | −3,000 | $144.22 | -$432.6K | EDGAR |
| 2026-09-16 | Andrew D Dickinson | Chief Financial Officer | Sell (S) | −3,000 | $145.29 | -$435.9K | EDGAR |
| 2026-09-11 | Johanna Mercier | Chief Comm & Corp Aff Officer | Mixed | +1,450 | $144.81 | -$195.1K | EDGAR |
| 2026-09-11 | Andrew D Dickinson | Chief Financial Officer | Mixed | +1,450 | $144.81 | -$195.1K | EDGAR |
| 2026-09-11 | Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | Mixed | +305 | $144.81 | -$41.3K | EDGAR |
| 2026-09-11 | Daniel Patrick O'Day | Chairman & CEO | Mixed | +4,550 | $144.81 | -$612.5K | EDGAR |
| 2026-09-11 | Dietmar Berger | Chief Medical Officer | Mixed | +270 | $144.81 | -$38.1K | EDGAR |
| 2026-09-02 | Daniel Patrick O'Day | Chairman & CEO | Sell (S) | −15,000 | $148.64 | -$2.23M | EDGAR |
| 2026-08-27 | Anthony Welters | Director | Mixed | — | $104.84 | -$1.58M | EDGAR |
| 2026-08-21 | Jeffrey Bluestone | Director | Mixed | — | $106.03 | -$389.9K | EDGAR |
| 2026-08-18 | Andrew D Dickinson | Chief Financial Officer | Sell (S) | −3,000 | $138.36 | -$415.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
GILD Insider Holdings
18 insiders · @ $156.04
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Daniel Patrick O'Day | Chairman & CEO | 569,683 | $88.89M | -$58.04M | 53 | 2026-10-02 |
| 2 | Andrew D Dickinson | Chief Financial Officer | 161,096 | $25.14M | -$62.65M | 73 | 2026-10-16 |
| 3 | Johanna Mercier | Chief Comm & Corp Aff Officer | 113,684 | $17.74M | -$32.30M | 58 | 2026-10-16 |
| 4 | Merdad Parsey | Chief Medical Officer | 84,621 | $13.20M | -$22.24M | 38 | 2024-12-11 |
| 5 | Diane E. Wilfong | Interim Corp Controller & CAO | 46,259 | $7.22M | -$3.79M | 25 | 2025-09-11 |
| 6 | Deborah H Telman | EVP, Corporate Affairs & GC | 43,676 | $6.82M | -$6.59M | 22 | 2025-11-13 |
| 7 | Sandra Patterson | SVP, Controllership | 40,077 | $6.25M | $0 | 13 | 2025-03-12 |
| 8 | Jacqueline K Barton | Director | 27,202 | $4.24M | $0 | 13 | 2026-05-04 |
| 9 | Dietmar Berger | Chief Medical Officer | 19,785 | $3.09M | $0 | 7 | 2026-09-11 |
| 10 | Anthony Welters | Director | 19,774 | $3.09M | -$2.68M | 10 | 2026-08-27 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
GILD Board & Officers
As of SEC filings through Oct 16, 2026Directors 9
- Kelly A. Kramer · since Aug 19, 2016
- Jacqueline K Barton · since Jan 31, 2018
- Harish Manwani · since May 9, 2018
- Daniel Patrick O'Day · since Feb 26, 2019
- Sandra Horning · since Jan 28, 2020
- Javier Rodriguez · since Jun 15, 2020
- Anthony Welters · since Oct 17, 2020
- Jeffrey Bluestone · since Dec 7, 2020
- Ted W Love · since Feb 1, 2024
Officers 7
- Daniel Patrick O'Day · Chairman & CEO · since Feb 26, 2019
- Andrew D Dickinson · Chief Financial Officer · listed since Mar 2021
- Dietmar Berger · Chief Medical Officer · since Jan 2, 2025
- Johanna Mercier · Chief Comm & Corp Aff Officer · listed since Feb 2026
- Wettan Keeley M Cain · EVP Gen Counsel, Legal & Comp · since Feb 4, 2026
- Diane E. Wilfong · Interim Corp Controller & CAO · listed since Mar 2025
- Erin Burkhart · SVP, Controllership · since Sep 22, 2025
Changes in the last 10 years (34)
| Feb 5, 2026 | Johanna Mercier listed as Chief Comm & Corp Aff Officer (previously Chief Commercial Officer) in SEC filings |
| Feb 4, 2026 | Wettan Keeley M Cain became EVP Gen Counsel, Legal & Comp |
| Nov 15, 2025 | The company announced the departure of Deborah H Telman as EVP, Corporate Affairs & GC in an SEC filing |
| Sep 22, 2025 | Erin Burkhart became SVP, Controllership |
| Mar 20, 2025 | Diane E. Wilfong listed as Interim Corp Controller & CAO (previously SVP, Controller & CAO) in SEC filings |
| Mar 12, 2025 | The company announced the departure of Sandra Patterson as SVP, Controllership in an SEC filing |
| Jan 2, 2025 | Dietmar Berger became Chief Medical Officer |
| Jul 17, 2024 | The company announced the departure of Merdad Parsey as Chief Medical Officer in an SEC filing |
| Mar 10, 2024 | The company announced the departure of Kevin E Lofton from the board in an SEC filing |
| Feb 1, 2024 | Ted W Love became a director |
| Mar 1, 2023 | Sandra Patterson became SVP, Controllership |
| Aug 1, 2022 | Deborah H Telman became EVP, Corporate Affairs & GC |
| May 25, 2022 | The company announced the departure of Brett A Pletcher as EVP,Corp Affairs & Gen Counsel in an SEC filing |
| Mar 12, 2021 | Andrew D Dickinson listed as Chief Financial Officer (previously EVP, Chief Financial Officer) in SEC filings |
| Dec 7, 2020 | Jeffrey Bluestone became a director |
| Oct 17, 2020 | Anthony Welters became a director |
| Jun 15, 2020 | Javier Rodriguez became a director |
| Jan 29, 2020 | Diane E. Wilfong became SVP, Controller & CAO |
| Jan 28, 2020 | Sandra Horning became a director |
| Nov 5, 2019 | Brett A Pletcher listed as EVP,Corp Affairs & Gen Counsel (previously EVP, Gen Counsel & Corp Sec) in SEC filings |
| Nov 1, 2019 | Merdad Parsey became Chief Medical Officer |
| Nov 1, 2019 | Andrew D Dickinson became EVP, Chief Financial Officer |
| Jul 1, 2019 | Johanna Mercier became Chief Commercial Officer |
| Feb 26, 2019 | Daniel Patrick O'Day became a director |
| Feb 26, 2019 | Daniel Patrick O'Day became Chairman & CEO |
| Sep 10, 2018 | Laura Hamill became EVP, Worldwide Commercial Ops |
| May 9, 2018 | Harish Manwani became a director |
| May 9, 2018 | Brett A Pletcher became EVP, Gen Counsel & Corp Sec |
| Apr 23, 2018 | John G McHutchison became Chief Scientific Off/HeadR&D |
| Mar 13, 2018 | John C Martin no longer listed as Executive Chairman in SEC filings |
| Feb 23, 2018 | James R Meyers reported in an SEC filing no longer being EVP Worldwide Commercial Ops |
| Feb 5, 2018 | Gregg H Alton listed as EVP,Corporate &Medical Affairs (previously EVP Comm&Acs ALA, Corp&Med Aff) in SEC filings |
| Jan 31, 2018 | Jacqueline K Barton became a director |
| Nov 21, 2016 | James R Meyers first listed as EVP Worldwide Commercial Ops in an SEC filing |
Not reported recently (14)
- Richard James Whitley · Last reported as a director in an SEC filing dated May 7, 2021
- Olsen Per Wold · Last reported as a director in an SEC filing dated May 7, 2021
- Gayle E Wilson · Last reported as a director in an SEC filing dated May 7, 2020
- John Francis Cogan · Last reported as a director in an SEC filing dated May 5, 2020
- Laura Hamill · Last reported as EVP, Worldwide Commercial Ops in an SEC filing dated May 10, 2019
- Robin L Washington · Last reported as EVP, CFO in an SEC filing dated Mar 14, 2019
- Gregg H Alton · Last reported as EVP,Corporate &Medical Affairs in an SEC filing dated Mar 5, 2019
- John C Martin · Last reported as a director in an SEC filing dated Feb 8, 2019
- John G McHutchison · Last reported as Chief Scientific Off/HeadR&D in an SEC filing dated Feb 8, 2019
- John F Milligan · Last reported as a director in an SEC filing dated Nov 29, 2018
- Nicholas G Moore · Last reported as a director in an SEC filing dated Apr 2, 2018
- Kevin Young · Last reported as Chief Operating Officer in an SEC filing dated Feb 23, 2018
- Norbert W Bischofberger · Last reported as EVP, R&D and CSO in an SEC filing dated Feb 23, 2018
- John W Madigan · Last reported as a director in an SEC filing dated May 11, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
GILD Proposed Insider Sales (Form 144)
Latest: 2026-10-15
? Form 144 Guide
Last 30d:
2 filings
· $937K notice value
· Last 90d:
9 filings
· $16.7M notice value
· 5 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
DANIEL O'DAY (1, $7.2M) · JOHANNA MERCIER (3, $4.8M) · ANTHONY WELTERS (1, $2.7M) · ANDREW DICKINSON (3, $1.3M) · JEFFREY BLUESTONE (1, $738K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 | JOHANNA MERCIER | Officer | 3,000 | $468.7K | 2026-10-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-15 | ANDREW DICKINSON | Officer | 3,000 | $468.7K | 2026-10-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-15 | JOHANNA MERCIER | Officer | 3,000 | $432.6K | 2026-09-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-15 | ANDREW DICKINSON | Officer | 3,000 | $435.9K | 2026-09-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-26 | ANTHONY WELTERS | Director | 18,000 | $2.68M | 2026-08-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-20 | JEFFREY BLUESTONE | Director | 5,000 | $738.0K | 2026-08-20 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-17 | JOHANNA MERCIER | Officer | 28,000 | $3.85M | 2026-08-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-17 | ANDREW DICKINSON | Officer | 3,000 | $415.1K | 2026-08-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-03 | DANIEL O'DAY | Director, Officer | 55,000 | $7.16M | 2026-08-03 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-15 | JOHANNA MERCIER | Officer | 3,000 | $389.8K | 2026-07-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-20
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-20 | 0001104659-26-064518 | EDGAR |
| 2026-05-07 | 0000882095-26-000022 | EDGAR |
| 2026-05-04 | 0000882095-26-000008 | EDGAR |
| 2026-04-28 | 0001104659-26-049874 | EDGAR |
| 2026-02-23 | 0001104659-26-018314 | EDGAR |
| 2026-02-10 | 0000882095-26-000003 | EDGAR |
| 2025-11-19 | 0001104659-25-113968 | EDGAR |
| 2025-10-30 | 0000882095-25-000044 | EDGAR |
| 2025-10-06 | 0000882095-25-000041 | EDGAR |
| 2025-08-14 | 0000882095-25-000035 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-24 | 0000882095-26-000006 | EDGAR |
| 2025-02-28 | 0000882095-25-000006 | EDGAR |
| 2024-02-23 | 0000882095-24-000007 | EDGAR |
| 2023-02-22 | 0000882095-23-000007 | EDGAR |
| 2022-02-23 | 0000882095-22-000007 | EDGAR |
| 2021-02-25 | 0000882095-21-000008 | EDGAR |
| 2020-02-25 | 0000882095-20-000006 | EDGAR |
| 2019-02-26 | 0000882095-19-000006 | EDGAR |
| 2018-02-27 | 0000882095-18-000008 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-07 | 0000882095-26-000024 | EDGAR |
| 2025-11-07 | 0000882095-25-000047 | EDGAR |
| 2025-08-07 | 0000882095-25-000032 | EDGAR |
| 2025-05-07 | 0000882095-25-000012 | EDGAR |
| 2024-11-12 | 0000882095-24-000028 | EDGAR |
| 2024-08-08 | 0000882095-24-000022 | EDGAR |
| 2024-05-08 | 0000882095-24-000013 | EDGAR |
| 2023-11-07 | 0000882095-23-000031 | EDGAR |
| 2023-08-04 | 0000882095-23-000025 | EDGAR |
| 2023-05-03 | 0000882095-23-000017 | EDGAR |
ETF Holders
502 ETFs hold GILD
25 shown · $31.08B total exposure · 0.42% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.25% | $5.9B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.28% | $4.9B | — | 2026-09-30 |
| 3 | QQQ Invesco QQQ Trust, Series 1 | Invesco | 0.86% | $4.1B | — | 2026-10-22 |
| 4 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.29% | $2.6B | $873.6B | 2026-10-22 |
| 5 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.30% | $2.4B | $810.5B | 2026-10-22 |
| 6 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.70% | $1.8B | — | 2026-09-30 |
| 7 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 2.96% | $1.4B | $47.7B | 2026-10-22 |
| 8 | VIG Vanguard Dividend Appreciation ETF | Vanguard | 0.82% | $1.0B | — | 2026-09-30 |
| 9 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 8.56% | $926.8M | $10.7B | 2026-10-22 |
| 10 | QQQM Invesco NASDAQ 100 ETF | Invesco | 0.86% | $915.3M | — | 2026-10-22 |
| 11 | VYM Vanguard High Dividend Yield ETF | Vanguard | 0.79% | $753.2M | — | 2026-09-30 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 2.59% | $565.5M | — | 2026-09-30 |
| 13 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.29% | $538.3M | $182.5B | 2026-10-22 |
| 14 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.52% | $437.9M | $84.5B | 2026-10-22 |
| 15 | DGRO iShares Core Dividend Growth ETF | iShares (BlackRock) | 0.93% | $415.7M | $44.5B | 2026-10-22 |
| 16 | QUAL iShares MSCI USA Quality Factor ETF | iShares (BlackRock) | 0.73% | $353.6M | $48.2B | 2026-10-22 |
| 17 | COWZ Pacer US Cash Cows 100 ETF | Nport | 1.83% | $333.4M | — | 2026-04-30 |
| 18 | DUHP Dimensional US High Profitability ETF | Dimensional | 1.35% | $259.8M | — | 2026-10-22 |
| 19 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.26% | $252.9M | $95.8B | 2026-10-22 |
| 20 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.29% | $252.2M | — | 2026-10-22 |
| 21 | IVW iShares S&P 500 Growth ETF | iShares (BlackRock) | 0.30% | $224.2M | $75.4B | 2026-10-22 |
| 22 | VV Vanguard Morningstar Large-Cap ETF | Vanguard | 0.29% | $217.7M | — | 2026-09-30 |
| 23 | USMV iShares MSCI USA Min Vol Factor ETF | iShares (BlackRock) | 0.90% | $217.3M | $24.1B | 2026-10-22 |
| 24 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.21% | $211.9M | — | 2026-10-22 |
| 25 | DGRW WisdomTree U.S. Quality Dividend Growth Fund | Nport | 1.25% | $208.2M | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.67
TTM Revenue
$30.46B
TTM Net Income
$-3.24B
TTM Op. Cash Flow
$13.55B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $7.80B | $-10.50B | $-8.45 | $3.57B |
| Q1 '26 | 2026-03-31 | $6.96B | $2.02B | $1.61 | $2.54B |
| Q4 '25 | 2025-12-31 | $7.92B | $2.18B | $1.74 | $3.33B |
| Q3 '25 | 2025-09-30 | $7.77B | $3.05B | $2.43 | $4.11B |
| Q2 '25 | 2025-06-30 | $7.08B | $1.96B | $1.56 | $827.00M |
| Q1 '25 | 2025-03-31 | $6.67B | $1.31B | $1.04 | $1.76B |
| Q4 '24 | 2024-12-31 | $7.57B | $1.78B | $1.42 | $2.98B |
| Q3 '24 | 2024-09-30 | $7.54B | $1.25B | $1.00 | $4.31B |
| Q2 '24 | 2024-06-30 | $6.95B | $1.61B | $1.29 | $1.32B |
| Q1 '24 | 2024-03-31 | $6.69B | $-4.17B | $-3.34 | $2.22B |
| Q4 '23 | 2023-12-31 | $7.11B | $1.43B | $1.13 | $2.17B |
| Q3 '23 | 2023-09-30 | $7.05B | $2.18B | $1.73 | $1.75B |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
16.63
P/S
6.41
EV/EBITDA
66.89
EV/Sales
7.09
ROE
-27.6%
ROA
-6.6%
Div Yield
2.09%
FCF Yield
6.94%
Debt/Equity
2.03
Current Ratio
—
Market Cap
$195.28B
as of 2026-10-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
21.83M
SI % of Float
1.77%
Days to Cover
3.36
Short Vol Ratio
51.7%
Free Float
1.24B
Float %
99.7%
Short interest 2026-09-30 • Short volume 2026-10-23 • Float 2026-08-07